(Q43806020)

27 November 2017

title

Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects (English)

1 reference

27 November 2017

1 reference

1 reference

Kobayashi J

1

1 reference

27 November 2017

Maruyama T

series ordinal

2

1 reference

27 November 2017

Masuda M

series ordinal

3

1 reference

27 November 2017

Shinomiya M

series ordinal

4

1 reference

27 November 2017

publication date

1 December 2001

1 reference

27 November 2017

1 reference

27 November 2017

volume

314

1 reference

27 November 2017

issue

1-2

1 reference

27 November 2017

page(s)

261-264

1 reference

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Comparison of statins in hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Effect of simvastatin (MK-733) on plasma triacylglycerol levels in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Cholesterol is required for the secretion of the very-low-density lipoprotein: in vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900701-X

10.1016/S0009-8981(01)00701-X

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference